1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc.

CTMX
CytomX Therapeutics, Inc.US flagNASDAQ Global Select
3.05
USD
+0.04
- -
491.11MMarket Cap

Total Valuation

CytomX Therapeutics, Inc. carries a market capitalization of 491.11M, placing it among publicly traded companies globally. Its enterprise value stands at 394.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap491.11M
Enterprise Value394.60M

Share Statistics

CytomX Therapeutics, Inc. currently has 217.69M shares outstanding.

Shares Outstanding217.69M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

CytomX Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 14.41. The price-to-sales ratio is 20.78, and the price-to-book ratio stands at -1.01.

PE Ratio14.41
PS Ratio20.78
PB Ratio-1.01
P/TBV Ratio2.32
P/FCF Ratio-9.23
P/OCF Ratio-9.22

Enterprise Valuation

The EV/Sales ratio of 11.10 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.99 provides insight into valuation relative to core operating earnings.

EV / Sales11.10
EV / EBITDA19.01
EV / EBIT19.99
EV / FCFN/A

Financial Position

CytomX Therapeutics, Inc. maintains a current ratio of 10.38, meaning it holds 10.4x the short-term assets needed to cover near-term liabilities.

Current Ratio10.38
Quick Ratio10.21
Debt / Equity0.89
Debt / EBITDA-0.05
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-25.83
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax234,000.00
Effective Tax RateN/A

Stock Price Statistics

CytomX Therapeutics, Inc.'s stock has gained approximately 24.13415% over the past 52 weeks. The 50-day moving average sits at 3.93, while the 200-day moving average is 4.04.

Beta (5Y)N/A
52-Week Price Change24.13415%
50-Day Moving Average3.93
200-Day Moving Average4.04
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, CytomX Therapeutics, Inc. generated 35.54M in revenue and converted that into -59.14M in net income, yielding earnings per share of -0.38. EBITDA reached -63.42M, while operating income came in at -64.66M.

Revenue35.54M
Gross ProfitN/A
Operating Income-64.66M
Pretax Income-58.91M
Net Income-59.14M
EBITDA-63.42M
EBIT-64.66M
Earnings Per Share (EPS)-0.38

Balance Sheet

CytomX Therapeutics, Inc. holds 346.71M in cash and equivalents against 2.86M in total debt, resulting in a net debt position of -28.83M. Total book value stands at -730.19M, with working capital of 319.07M providing operational flexibility.

Cash & Cash Equivalents346.71M
Total Debt2.86M
Net Debt-28.83M
Equity (Book Value)-730.19M
Book Value Per Share-4.65
Working Capital319.07M

Cash Flow

CytomX Therapeutics, Inc. produced -80.09M in operating cash flow over the past twelve months. After subtracting -101,000.00 in capital expenditures, free cash flow totaled -80.19M - equivalent to -0.51 per share.

Operating Cash Flow-80.09M
Capital Expenditures-101,000.00
Free Cash Flow-80.19M
FCF Per Share-0.51

Margins

CytomX Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -181.92 and net profit margin of -166.40 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-181.92
Pretax Margin-165.74
Profit Margin-166.40
EBITDA Margin-178.43

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-46.71
FCF Yield-10.83

Scores

CytomX Therapeutics, Inc. posts an Altman Z-Score of 8.96, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score8.96